Commercializing Cell and Gene Therapies in Canada
Pharmaceutical Commerce, Sandra Anderson
Cell and gene therapies (CGT) are currently at the forefront of scientific innovation. They hold great promise for patients suffering from a range of serious ailments. But because these therapies are new, often distinct in their makeup, and often targeted to a small patient population, they pose considerable challenges for the pharmaceutical companies seeking to bring them to market. While there are many such drugs in development, few have made it through the commercialization process to date. Still, by seeking to create standard models for commercialization and leveraging the expertise of those with experience bringing other complex therapies to market, these trailblazers can find success.
For the full article, please visit Pharmaceutical Commerce.